Product Description
a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02281201)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CSL Behring
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Injuries/wounds Unspecified|Blood Coagulation Disorders|Hemostatic Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
TAP Study | P3 |
Terminated |
Injuries/wounds Unspecified |
2024-10-29 |
|
BE1116_3004 | P3 |
Completed |
Blood Coagulation Disorders|Hemostatic Disorders |
2016-01-01 |
|
2005-000382-19 | P3 |
Completed |
Injuries/wounds Unspecified |
2006-11-08 |